Resources

Presentations

Corporate Presentation - August 2022

November 11, 2021

Research and Development Day Presentation - November 2021

Milademetan Posters & Presentations

ASCO 2022

Vijaya G. Tirunagaru, Feng Xu, Trista Hinz, Lynn E. Heasley, Richard Bryce, Avanish Vellanki, Nora Ku, and Robert C. Doebele

Using CDKN2A loss in the context of wild-type TP53 to predict sensitivity for the MDM2 inhibitor milademetan

ASCO 2022

Mrinal M. Gounder, Gary K. Schwartz, Robin L. Jones, Sant P. Chawla, Victoria S. Chua-Alcala, Silvia Stacchiotti, Andrew J. Wagner, Gregory M. Cote, Robert G. Maki, Hanna Kosela-Paterczyk, Dale R. Shepard, Naisargee Shah, Richard Bryce, Robert C. Doebele, Shreyaskumar Patel

MANTRA: A randomized, multicenter, phase 3 study of the MDM2 inhibitor milademetan (RAIN-32) versus trabectedin in patients with dedifferentiated liposarcoma

ASCO 2022

Ecaterina E. Dumbrava, Glenn J. Hanna, Gregory M. Cote, Thomas Stinchcombe, Melissa Johnson, Christopher T. Chen, Siddhartha Devarakonda, Naisargee Shah, Feng Xu, Robert C. Doebele, Mrinal M. Gounder

MANTRA-2: A phase 2 study of the MDM2 inhibitor milademetan in patients with TP53 wild-type and MDM2-amplified advanced or metastatic solid tumors

AACR 2022

Mrinal M. Gounder, Gary K. Schwartz, Robin L. Jones, Sant P. Chawla, Victoria S. Chua-Alcala, Silvia Stacchiotti, Andrew J. Wagner, Gregory M. Cote, Robert G. Maki, Hanna Kosela-Paterczyk, Dale R. Shepard, Naisargee Shah, Richard Bryce, Robert C. Doebele, Shreyaskumar Patel

MANTRA: A randomized, multicenter, phase 3 study of the MDM2 inhibitor milademetan (RAIN-32) versus trabectedin in patients with dedifferentiated liposarcoma

AACR 2022

Ecaterina E. Dumbrava, Glenn J. Hanna, Gregory M. Cote, Thomas Stinchcombe, Melissa Johnson, Christopher T. Chen, Siddhartha Devarakonda, Naisargee Shah, Feng Xu, Robert C. Doebele, Mrinal M. Gounder

MANTRA-2: A phase 2 study of the MDM2 inhibitor milademetan in patients with TP53 wild-type and MDM2-amplified advanced or metastatic solid tumors

AACR 2022

Vijaya G. Tirunagaru, Feng Xu and Robert C. Doebele

Exploration of MDM2 gene amplification, co-mutation status, and prognosis in solid tumors

AACR-NCI-EORTC 2021

Vijaya G. Tirunagaru, PH.D.

MDM2gene amplification as a predictive biomarker for the MDM2 inhibitor milademetan

AACR-NCI-EORTC 2021

Vijaya Tirunagaru, Ph.D.

The MDM2 inhibitor milademetan induces synthetic lethality in GATA3 mutant, ER positive breast cancer

AACR-NCI-EORTC 2021

Varsha Ananthapadmanabhan, Ph.D.

Milademetan is a potent, murine double minute 2 (MDM2) inhibitor, highly active in TP53 wild-type (p53WT) Merkel cell carcinoma (MCC) cell lines

IASLC 2021 World Conference on Lung Cancer

Lynn Heasley, Ph.D.

The MDM2/p53 axis is a therapeutic vulnerability in malignant pleural mesothelioma

EORTC-NCI-AACR 2020

Mrinal M. Gounder

Milademetan (DS-3032b or RAIN-32), an Oral MDM2 Inhibitor, in Well-Differentiated/Dedifferentiated Liposarcoma: Results From a Phase 1 Study in Patients With Solid Tumors or Lymphomas

ASH 2019

Courtney D. DiNardo

A Phase 1 Dose-Escalation Study of Milademetan in Combination With 5-Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

ASH 2019

A Phase 1 Study of Milademetan in Combination With Quizartinib in Patients With Newly Diagnosed (ND) or Relapsed/Refractory (R/R) FLT3-ITD Acute Myeloid Leukemia (AML)

ESMO 2019

A Phase 2 biomarker-driven study evaluating the clinical efficacy of MDM2 inhibitor, milademetan, in patients with intimal sarcoma, a disease with a high unmet need

Rad52 posters & presentations

Targeting BRCA1- and BRCA2-deficient cells with RAD52 small molecule inhibitors

Nucleic Acids Res. 2016 May 19;44(9):4189-99

Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells

Cell Rep. 2018 Jun 12;23(11):3127-3136.